metaEvidence - overview


deaths (OS)	progression or deaths (PFS)	RFS/DFS
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus placebo plus SoC
	sintillimab plus SoC vs. placebo plus SoC	1		-
versus Standard of Care (SoC)
	cemiplimab vs. Standard of Care (SoC)	1		-
	durvalumab alone vs. Standard of Care (SoC)	1	-	-
mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative
versus pemetrexed plus platin
	nivolumab plus SoC vs. pemetrexed plus platin	1		-
mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive
versus Standard of Care (SoC)
	atezolizumab alone vs. Standard of Care (SoC)	3		-
	cemiplimab vs. Standard of Care (SoC)	1		-
	durvalumab alone vs. Standard of Care (SoC)	1		-
	nivolumab alone vs. Standard of Care (SoC)	2		-
	pembrolizumab alone vs. Standard of Care (SoC)	4		-
mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb
non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population
versus atezolizumab plus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel	1		-
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1		-
	atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	1		-
non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel	2		-
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1		-
versus pemetrexed plus platin
	atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin	1		-
	pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin	1		-
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1		-
squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population
versus carboplatin plus nab-paclitaxel
	atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel	1		-
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	1		-

deaths (OS)

progression or deaths (PFS)

RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

sintillimab plus SoC vs. placebo plus SoC

cemiplimab vs. Standard of Care (SoC)

durvalumab alone vs. Standard of Care (SoC)

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

nivolumab plus SoC vs. pemetrexed plus platin

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

atezolizumab alone vs. Standard of Care (SoC)

cemiplimab vs. Standard of Care (SoC)

durvalumab alone vs. Standard of Care (SoC)

nivolumab alone vs. Standard of Care (SoC)

pembrolizumab alone vs. Standard of Care (SoC)

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel

atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel

atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel

atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel

atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin

pembrolizumab and pemetrexed plus platin vs. pemetrexed plus platin

pembrolizumab plus SoC vs. placebo plus SoC

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel

pembrolizumab plus SoC vs. placebo plus SoC